Status:
UNKNOWN
The Culture of Advanced or Recurrent Ovarian Cancer Organoids and Drug Screening
Lead Sponsor:
Chongqing University Cancer Hospital
Conditions:
Ovarian Neoplasms
Eligibility:
FEMALE
18-70 years
Brief Summary
Most ovarian cancer will relapse after standard therapy. Patients with recurrent ovarian cancer are resistant to platinum. Due to the high heterogeneity between ovarian cancer, individual precise ther...
Detailed Description
This trial is a single-arm and prospective observational study. The subjects are the advanced or recurrent ovarian cancer patients, who are planned to undergo surgery, but the neoplastic lesions can't...
Eligibility Criteria
Inclusion
- Patients voluntarily participated in the study and signed informed consent;
- The tumour cannot be excised thoroughly by surgery;
- ECOG score ≤ 2;
- Expected survival \>6 months;
- Blood routine test: Hb≥70g/L、WBC≥3.5×109/ L 、ANC≥1.5×109/L、PLT≥80×109/L;
- Both serum ALT and serum AST ≤ 2 × ULN； blood creatinine ≤ 1.5 × ULN;
- Unpregnant women (negative HCG) received contraception in the study;
- Good compliance is judged by researchers.
Exclusion
- Active or the uncontrol serious infections;
- Patients with liver cirrhosis, decompensated liver disease, active hepatitis or chronic hepatitis need antiviral treatment;
- A history of immune deficiency, including HIV positive or other acquired congenital immune deficiency diseases;
- Chronic renal insufficiency and renal failure;
- Myocardial infarction, severe arrhythmia and congestive heart failure (≥ grade 2 according to NYHA classification);
- Autoimmune diseases, including systemic lupus erythematosus;
- Patients take drugs that damage liver and kidney function for other complications, such as tuberculosis;
- Patients cannot understand the experimental contents and refuse to sign the informed consent form;
- Other concomitant serious diseases harm the health of patients or interfere with the study.
Key Trial Info
Start Date :
March 9 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05290961
Start Date
March 9 2022
End Date
December 31 2024
Last Update
August 31 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China, 400000